Skip to content
Stribild(cobicistat)
Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Symtuza, Tybost (cobicistat) is a small molecule pharmaceutical. Cobicistat was first approved as Stribild on 2012-08-27. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Tybost
Combinations
Evotaz, Genvoya, Prezcobix, Stribild, Symtuza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atazanavir sulfate
+
Cobicistat
Tradename
Company
Number
Date
Products
EVOTAZBristol Myers SquibbN-206353 RX2015-01-29
1 products, RLD, RS
Cobicistat
Tradename
Company
Number
Date
Products
TYBOSTGilead SciencesN-203094 RX2014-09-24
1 products, RLD, RS
Cobicistat
+
Darunavir
Tradename
Company
Number
Date
Products
PREZCOBIXJohnson & JohnsonN-205395 RX2015-01-29
1 products, RLD, RS
Cobicistat
+
Darunavir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
SYMTUZAJohnson & JohnsonN-210455 RX2018-07-17
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
GENVOYAGilead SciencesN-207561 RX2015-11-05
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
evotazNew Drug Application2020-07-31
genvoyaNew Drug Application2022-01-13
prezcobixNew Drug Application2023-04-10
stribildNew Drug Application2021-09-16
symtuzaNew Drug Application2021-08-05
tybostNew Drug Application2020-12-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
Expiration
Code
COBICISTAT, TYBOST, GILEAD SCIENCES INC
2026-08-22ODE-260
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods
107865182038-07-19U-2978
87540652032-08-15DS, DPU-257, U-2352, U-2765
92967692032-08-15DS, DPU-257, U-2352, U-2765
73907912025-04-17DS, DP
Atazanavir Sulfate / Cobicistat, Evotaz, Bristol
100397182032-10-06DP
81483742029-09-03DS, DPU-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768, U-2939
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc
86332192030-04-30DPU-257
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
Cobicistat / Darunavir, Prezcobix, Janssen Prods
77006452026-12-26DS, DP
85189872024-02-16DS, DP
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc
85923972024-01-13DPU-257
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AR: Antivirals for treatment of hiv infections, combinations
J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
J05AR14: Darunavir and cobicistat
J05AR15: Atazanavir and cobicistat
J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
V: Various drug classes in atc
V03: All other therapeutic products
V03A: All other therapeutic products
V03AX: Other therapeutic products in atc
V03AX03: Cobicistat
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20341011431
HivD006678O98.78147323
Healthy volunteers/patients11213
Acquired immunodeficiency syndromeD000163EFO_0000765B2014116
NeoplasmsD009369C80112
Opioid-related disordersD009293EFO_0005611F1111
Chronic hepatitis cD019698EFO_0004220B18.211
Metabolic bone diseasesD001851HP_000093811
CoinfectionD06008511
Sleep wake disordersD012893G4711
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D015497112
CoronavirusD017934112
PregnancyD011247EFO_0002950Z33.111
Pneumocystis pneumoniaD011020EFO_0007448B5911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544112
Myeloid leukemia acuteD015470C92.0111
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0111
Biphenotypic leukemia acuteD015456C95.0111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B5422
Hepatitis cD006526B19.211
Insulin resistanceD007333EFO_000261411
Non-small-cell lung carcinomaD00228911
Latent tuberculosisD055985Z22.711
PharmacokineticsD01059911
Drug interactionsD00434711
Pancreatic ductal carcinomaD02144111
Pancreatic neoplasmsD010190EFO_0003860C2511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TuberculosisD014376EFO_0000774A15-A1911
Job syndromeD007589EFO_0003775D82.411
Acute kidney injuryD058186HP_0001919N1711
Chronic hepatitis bD019694EFO_0004197B18.111
Bone diseasesD001847M89.911
Sexually transmitted diseasesD012749A50-A6411
Covid-19D000086382U07.111
PneumoniaD011014EFO_0003106J1811
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCOBICISTAT
INNcobicistat
Description
Cobicistat is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoic acid with the amino group of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-amino-1,6-diphenylhexan-2-yl]carbamate. Acts as a pharmacoenhancer in treatment of HIV-1 by inhibiting P450 enzymes that metabolise other medications.. It has a role as a P450 inhibitor. It is a member of 1,3-thiazoles, a member of morpholines, a member of ureas, a carbamate ester and a monocarboxylic acid amide.
Classification
Small molecule
Drug classenzyme inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Identifiers
PDB
CAS-ID1004316-88-4
RxCUI1306284
ChEMBL IDCHEMBL2095208
ChEBI ID72291
PubChem CID25151504
DrugBankDB09065
UNII IDLW2E03M5PG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Stribild - Gilead Sciences
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Genvoya - Gilead Sciences
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,495 documents
View more details
Safety
Black-box Warning
Black-box warning for: Genvoya, Stribild, Symtuza
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
17,594 adverse events reported
View more details